Shares in France's Eurofins rally as it targets more coronavirus products

French laboratories and diagnostics company Eurofins said it hoped to launch more products aimed at detecting the presence of the coronavirus, as it posted an increase in first-half profits, sending its shares to record highs.

By Sudip Kar-Gupta

PARIS, Aug 6 (Reuters) - French laboratories and diagnostics company Eurofins EUFI.PA said it hoped to launch more products aimed at detecting the presence of the coronavirus, as it posted an increase in first-half profits, sending its shares to record highs.

Net profits rose 60.9% from a year earlier to 95 million euros ($113 million).

Revenues increased 7.2% to 2.323 billion euros and Eurofins said it was confident of meeting its 2020 financial targets, which include reaching 5 billion euros of revenues.

Eurofins has launched an array of products to detect the presence of SARS-CoV-2 virus responsible for the COVID-19 disease, buoying its overall performance.

Eurofins shares were up by around 10% in early session trading, at all-time highs. The stock has risen by roughly 30% since the start of 2020, giving Eurofins a market capitalisation of around 12 billion euros.

"A strong performance across the board," wrote brokerage Jefferies, keeping a 'buy' rating on Eurofins' shares.

($1 = 0.8415 euros)

(Reporting by Sudip Kar-Gupta Editing by Shri Navaratnam and Edmund Blair)

((sudip.kargupta@thomsonreuters.com; +33 1 49 49 53 84;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More